Sun Pharma Reports Q4 & Full Year Results for FY26; Proposes Rs. 5 Dividend

Sun Pharma Reports Q4 & Full Year Results for FY26; Proposes Rs. 5 Dividend​

Sun Pharmaceutical Industries Limited announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company reported strong growth in sales and profitability across its global operations, confirming its position as a leading global pharmaceutical enterprise.

The Board of Directors of the company, at a meeting held on May 22, 2026, approved the audited financial results. In addition to these results, the Board proposed a final dividend of Rs. 5.00 per equity share for the financial year 2026. This recommendation brings the total dividend for FY26 to Rs. 16.00 per share, matching the rate declared in FY25.

Financial Performance Overview​

The company's overall performance demonstrated robust year-over-year growth.

For the full year FY26, total sales reached Rs. 582,201 million, marking an 11.9% growth compared to the previous financial year. Consolidated EBITDA for the full year stood at Rs. 177,314 million, representing a 16.1% increase. Net profit for FY26 was Rs. 114,794 million, growing by 5.0%.

The fourth quarter (Q4FY26) results showed significant quarter-on-quarter acceleration, with sales reaching Rs. 145,598 million (up 13.6% year-over-year). Quarterly Net profit for Q4FY26 was Rs. 27,140 million, a 26.2% increase year-over-year.

Consolidated Financial Results Snapshot (₹ in Millions)​

Global Revenue Streams​

The company’s revenue streams showed diversification and sustained growth across key markets.

• India Formulations: Formulation sales in India were Rs. 48,359 million in Q4FY26, showing a 14.8% increase. For the full year FY26, India Formulations sales amounted to Rs. 192,904 million, representing 14% growth and contributing 33.2% of the total consolidated sales.
• Innovative Medicines: This specialized segment remains a key growth driver. Global Innovative Medicines sales reached US$ 354 million in Q4FY26, up 20.1%. For the full year FY26, sales totaled US$ 1,420 million, an increase of 16.8%.
• Emerging Markets (EM) Formulations: EM sales recorded US$ 306 million in Q4FY26 (up 17.4%), contributing US$ 1,265 million for the full year FY26, a 13.6% growth.
• Rest of World (ROW) Formulations: RoW markets achieved US$ 220 million in Q4FY26 (up 10%). For FY26, RoW Formulations generated US$ 969 million, an increase of 14.4%.
• US Formulations: Sales of US Formulations were US$ 459 million in Q4FY26. For the full year FY26, US Formulations totaled US$ 1,904 million.

Operational and Strategic Updates​

The company highlighted several strategic milestones, including the ongoing acquisition of Organon & Co., which is expected to accelerate its transformation into a major global player.

In Research and Development, Sun Pharma reported that R&D investment was at 6.7% of sales during Q4FY26 and 6.1% of sales for the full year FY26, emphasizing its commitment to building its innovative pipeline.

The company continues to develop its specialized portfolio, with five novel entities currently in the clinical stage, including candidates for treating psoriatic arthritis (Ilumya) and soft tissue sarcoma glioblastoma (Fibromun).

Consolidated Balance Sheet Overview​

The company reported a total asset value of 1,087,852.2 million at March 31, 2026, compared to 921,005.8 million at March 31, 2025. This represented a robust expansion across multiple asset classes.

<table>
<thead>
<tr>
<th>Particulars</th>
<th>As at 31.03.2026 (₹ Million)</th>
<th>As at 31.03.2025 (₹ Million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Non-current Assets</td>
<td>448,940.3</td>
<td>394,761.1</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>28,647.7</td>
<td>25,278.6</td>
</tr>
<tr>
<td>TOTAL ASSETS</td>
<td>1,087,852.2</td>
<td>921,005.8</td>
</tr>
<tr>
<td>Total Equity</td>
<td>838,797.4</td>
<td>724,859.5</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>249,054.8</td>
<td>196,146.3</td>
</tr>
</tbody>
</table>

SUNPHARMA Stock Price Movement​

Today, shares of Sun Pharmaceutical Industries Limited slipped by 2.44% to settle at ₹1840.8 in post-market trading. The equity shed ₹46.10 on a substantial volume of 2.80 million shares, notably trading significantly below its 52-week high of ₹1916.6.